Kazutaka Oda

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 20

Top Topics

Pseudomonas Aeruginosa

Patients Undergoing

Biofilm Formation

Top Venues

British journal of clinical pharmacology

Antibiotics (Basel, Switzerland)

Journal of pharmaceutical health care and sciences

Therapeutic drug monitoring

This page only lists publications with an associated author ORCID identifier.

Publications

Kazutaka Oda, Hirofumi Jono, Hideyuki Saito
Optimizing Cefiderocol Dosing Through Population Pharmacokinetic/Pharmacodynamic Simulation: An Assessment of Drug Cost Reductions. Therapeutic drug monitoring (2024)
Tomoyuki Yamada, Kazutaka Oda, Masami Nishihara, Masashi Neo
A simulation study on model-informed precision dosing of amikacin for achieving target area under the concentration-time curve. British journal of clinical pharmacology (2024)
Tomoyuki Yamada, Kazutaka Oda, Masami Nishihara, Masashi Neo
A simulation study on model-informed precision dosing of amikacin for achieving target area under the concentration-time curve. British journal of clinical pharmacology 90 (4) (2024)
Kazutaka Oda, Tomomi Katanoda, Hitomi Arakaki, Taiki Katsume, Kaho Matsuyama, Hirofumi Jono, Hideyuki Saito
Thiamylal serum concentration for refractory convulsive status epilepticus while associated decreased concentrations of concomitant antiepileptics: a case report. Journal of pharmaceutical health care and sciences 10 (1) (2024)
Tomoyuki Yamada, Kazutaka Oda, Masami Nishihara, Masashi Neo
A simulation study on model-informed precision dosing of amikacin for achieving target area under the concentration-time curve. British journal of clinical pharmacology 90 (4) (2024)
Tomoyuki Yamada, Kazutaka Oda, Masami Nishihara, Masashi Neo
A simulation study on model-informed precision dosing of amikacin for achieving target area under the concentration-time curve. British journal of clinical pharmacology 90 (4) (2024)
Kazutaka Oda, Tomomi Katanoda, Hitomi Arakaki, Taiki Katsume, Kaho Matsuyama, Hirofumi Jono, Hideyuki Saito
Thiamylal serum concentration for refractory convulsive status epilepticus while associated decreased concentrations of concomitant antiepileptics: a case report. Journal of pharmaceutical health care and sciences 10 (1) (2024)
Hajime Nakashima, Motoyasu Miyazaki, Tsuneo Kuwamura, Kazutaka Oda, Yumi Haga, Osamu Imakyure
Relationship between Target Time above Minimum Inhibitory Concentration Achievement Rate of Meropenem Using Monte Carlo Simulation and In-Hospital Survival in Patients with Pseudomonas aeruginosa Bacteremia. Antibiotics (Basel, Switzerland) 13 (3) (2024)
Junji Saruwatari, Tetsuya Kaneko, Tsukasa Murata, Haruka Narise, Sawa Kugimoto, Eri Nishimura, Natsuki Tetsuka, Misaki Ando, Momo Oi, Masako Ota, Nayumi Hamada, Keiichiro Kaneda, Shiro Furusho, Masakatsu Sakamoto, Ayami Kajiwara-Morita, Kazutaka Oda, Kentaro Oniki, Keishi Ueda, Hirofumi Jono, Yasui-Furukori Norio
Effect of concomitant use of yokukansan on steady-state blood concentrations of donepezil and risperidone in real-world clinical practice. Neuropsychopharmacology reports (2024)
Hajime Nakashima, Motoyasu Miyazaki, Tsuneo Kuwamura, Kazutaka Oda, Yumi Haga, Osamu Imakyure
Relationship between Target Time above Minimum Inhibitory Concentration Achievement Rate of Meropenem Using Monte Carlo Simulation and In-Hospital Survival in Patients with Pseudomonas aeruginosa Bacteremia. Antibiotics (Basel, Switzerland) 13 (3) (2024)
Tomoyuki Yamada, Kazutaka Oda, Masami Nishihara, Masashi Neo
A simulation study on model-informed precision dosing of amikacin for achieving target area under the concentration-time curve. British journal of clinical pharmacology 90 (4) (2024)
Tomoyuki Yamada, Kazutaka Oda, Masami Nishihara, Masashi Neo
A simulation study on model-informed precision dosing of amikacin for achieving target area under the concentration-time curve. British journal of clinical pharmacology 90 (4) (2024)
Tomoyuki Yamada, Kazutaka Oda, Masami Nishihara, Masashi Neo
A simulation study on model-informed precision dosing of amikacin for achieving target area under the concentration-time curve. British journal of clinical pharmacology 90 (4) (2024)
Hajime Nakashima, Motoyasu Miyazaki, Tsuneo Kuwamura, Kazutaka Oda, Yumi Haga, Osamu Imakyure
Relationship between Target Time above Minimum Inhibitory Concentration Achievement Rate of Meropenem Using Monte Carlo Simulation and In-Hospital Survival in Patients with Pseudomonas aeruginosa Bacteremia. Antibiotics (Basel, Switzerland) 13 (3) (2024)
Kazutaka Oda, Tomomi Katanoda, Hitomi Arakaki, Taiki Katsume, Kaho Matsuyama, Hirofumi Jono, Hideyuki Saito
Thiamylal serum concentration for refractory convulsive status epilepticus while associated decreased concentrations of concomitant antiepileptics: a case report. Journal of pharmaceutical health care and sciences 10 (1) (2024)
Kazutaka Oda, Hirofumi Jono, Hidenobu Kamohara, Hideyuki Saito
Population Pharmacokinetic Modeling of Unbound Meropenem in Patients Undergoing Continuous Renal Replacement Therapy: An Observational Cohort Study. Therapeutic drug monitoring (2024)
Kazutaka Oda, Hirofumi Jono, Hideyuki Saito
Model-Informed Precision Dosing of Vancomycin in Adult Patients Undergoing Hemodialysis. Antimicrobial agents and chemotherapy (2023)
Kazutaka Oda, Tomoyuki Yamada, Kazuaki Matsumoto, Yuki Hanai, Takashi Ueda, Masaru Samura, Akari Shigemi, Hirofumi Jono, Hideyuki Saito, Toshimi Kimura
Model-informed precision dosing of teicoplanin for the rapid achievement of the target area under the concentration-time curve: A simulation study. Clinical and translational science (2023)
Kazutaka Oda, Tomoyuki Yamada, Kazuaki Matsumoto, Yuki Hanai, Takashi Ueda, Masaru Samura, Akari Shigemi, Hirofumi Jono, Hideyuki Saito, Toshimi Kimura
Model-informed precision dosing of vancomycin for rapid achievement of target area under the concentration-time curve: A simulation study. Clinical and translational science (2023)
Kazutaka Oda, Yumi Hashiguchi, Tomomi Katanoda, Hirotomo Nakata, Hirofumi Jono, Hideyuki Saito
Lowered Risk of Nephrotoxicity through Intervention against the Combined Use of Vancomycin and Tazobactam/Piperacillin: A Retrospective Cohort Study. Microbiology spectrum 9 (1) (2021)